Physician profile
Kantam L Gade
NPI 1659411205
$4,877.39
in general payments reported to CMS, 2019-2025
44 companies · $19.75 in 2025
The $19.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $1,087 · 2021: $1,655 · 2022: $832 · 2023: $15.92 · 2024: $28.67 · 2025: $19.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $553.16 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $441.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $413.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $266.80 | 2019-2022 | |
| Novo Nordisk INC | $230.76 | 2019-2022 | |
| Esperion Therapeutics, INC. | $222.72 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $206.84 | 2019-2024 | |
| Akcea Therapeutics, INC. | $200.45 | 2019 | |
| Daiichi Sankyo INC. | $165.81 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.99 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $143.68 | 2020-2021 | |
| Pacira Therapeutics, INC. | $142.41 | 2019-2021 | |
| Astellas Pharma US INC | $137.00 | 2019-2021 | |
| Abbott Laboratories | $135.63 | 2019-2022 | |
| Amarin Pharma, INC. | $132.57 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kantam Gade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.